Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Descartes-08
Descartes 11 · 1 trial · 1 indication
Per IMWG 2016 Response Criteria Summary sCR: Complete response (CR) plus a normal free light chain ratio and no clonal cells in bone marrow (by immunohistochemistry). The FLC ratio must be Kappa/Lambda ≤ 4:1 or ≥ 1:2 after counting at least 100 plasma cells. CR: Negative immunofixation in serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. VGPR: Serum M-protein detectable by immunofixation (not on electrophoresis) or a ≥ 90% reduction in M-protein, with urine M-protein \<100 mg/24 hours. PR: ≥ 50% reduction in serum M-protein and a ≥ 90% reduction in 24-hour urinary M-protein (or to \<200 mg/24 hours). If M-protein is unmeasurable, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required. If both M-protein and serum-free light chains are unmeasurable, a ≥ 50% reduction in plasma cells is necessary, provided baseline plasma-cell percentage in bone marrow was ≥ 30%. Overall Response (OR): CR+VGPR+PR
| Arm | Type | Description |
|---|---|---|
| Descartes 11 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Descartes 11 | BIOLOGICAL | Car T-cells |
Inclusion Criteria: * Patients must be 18 years of age or older at the time of enrollment * High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs). Exclusion Criteria: * Patients who are pregnant or lactating. * Patient...
Top 20 of 25 competitors
Descartes 11 is an investigational monoclonal antibody being developed by Cartesian Therapeutics for use in multiple myeloma. It is specifically being studied as a consolidation treatment in patients with high-risk multiple myeloma who have residual disease after induction therapy. The drug is currently in Phase 2 clinical development.
Descartes 11 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being investigated for its potential role in treating multiple myeloma, particularly as a consolidation therapy for patients with residual disease after initial treatment.
Descartes 11 is being developed by Cartesian Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol RNAC. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with multiple myeloma.
Descartes 11 is currently in Phase 2 clinical development. A Phase 2 clinical trial (NCT04436029) evaluating the drug as a consolidation treatment in patients with high-risk multiple myeloma has been completed. The drug is investigational and has not been approved by regulatory authorities.
Descartes 11 has been studied in one clinical trial, NCT04436029, a Phase 2 study titled 'Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy.' This trial enrolled 5 participants in the United States and has been completed.
No, Descartes 11 and Descartes-08 are different drug candidates developed by Cartesian Therapeutics. Descartes-08 is being studied for autoimmune conditions such as generalized myasthenia gravis and systemic lupus erythematosus, while Descartes 11 is being evaluated for multiple myeloma. They are distinct investigational therapies.